Teva Offers To Buy Mylan In $40.1b Cash-and-stock Deal

TRENTON, N.J. (AP) — Generic drug giant Teva formally offered to buy fellow drugmaker Mylan about $40.1 billion in cash and stock on Tuesday, despite Mylan's cold shoulder and the certainty the proposed acquisition will bring intense scrutiny by antitrust regulators. If Israel-based Teva Pharmaceutical Industries Ltd. succeeded, the combination would dominate the global generic drug market, be a major contender in some other specialty drug categories — and have the leverage to try to raise generic drugs prices. On Friday, the Dutch company said anti-trust regulators probably wouldn't approve a deal and said it prefers to remain a stand-alone company and instead buy generic drug and ingredients maker Perrigo Co.

 

Welcome to Wopular!

Welcome to Wopular

Wopular is an online newspaper rack, giving you a summary view of the top headlines from the top news sites.

Senh Duong (Founder)
Wopular, MWB, RottenTomatoes

Subscribe to Wopular's RSS Fan Wopular on Facebook Follow Wopular on Twitter Follow Wopular on Google Plus

MoviesWithButter : Our Sister Site

More Business News